Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co Buyback Yield % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sun Pharma Advanced Research Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sun Pharma Advanced Research Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sun Pharma Advanced Research Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Sun Pharma Advanced Research Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sun Pharma Advanced Research Co (BOM:532872) has a Buyback Yield % of 0.00 as of Aug. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sun Pharma Advanced Research Co and its competitors. According to the industry distribution chart, Sun Pharma Advanced Research Co ranks #999999 out of 279 companies in the Drug Manufacturers industry.
Is Sun Pharma Advanced Research Co's Buyback Yield % too high?
Sun Pharma Advanced Research Co's current Buyback Yield % is 0.00. Based on the distribution chart, Sun Pharma Advanced Research Co ranks #999999 out of 279 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sun Pharma Advanced Research Co ranks #999999 out of 279 companies for Buyback Yield %. This places Sun Pharma Advanced Research Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sun Pharma Advanced Research Co and its competitors. Sun Pharma Advanced Research Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (BOM:532872) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹83.02, compared to a current price of ₹208.10 — trading 150.7% above its estimated fair value. The current Buyback Yield % is 0.00. Sun Pharma Advanced Research Co's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (BOM:532872), the current Buyback Yield % is 0.00 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sun Pharma Advanced Research Co (BOM:532872) Overvalued in 2026?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be overvalued.
The current stock price of ₹208.10 is trading 150.7% above its estimated GF Value™ of ₹83.02.
GuruFocus considers Sun Pharma Advanced Research Co to be Significantly Overvalued.
Key valuation signals for BOM:532872:
Buyback Yield %: 0.00
GF Value™: ₹83.02 vs. price of ₹208.10 (150.7% above fair value)
No single metric tells the full story. See the BOM:532872 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
39GF Score
Get the complete analysis for BOM:532872
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532872 has been successfully added to your 
